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At least eight diseases (Huntington’s disease (HD), spino-
bulbar muscular atrophy (SBMA or Kennedy’s disease), den-
tatorubral-pallidoluysian atrophy (DRPLA), and spinocere-
bellar ataxias (SCAs) types 1, 2, 3, 6, and 7) are now
known to be associated with a polyglutamine stretch which
is greatly expanded in a¡ected individuals [1,2]. While the
function of only two of these genes is known (the gene for
SBMA is the androgen receptor, and the gene for SCA6 is a
sodium channel), it is clear from the DNA and protein se-
quences that the genes are diverse and unrelated. Thus, an
expanded polyglutamine stretch itself may somehow play a
role in disease etiology.
The study of the structure of polyglutamine has a long
history. Apparently the ¢rst to study the structure of polyglut-
amine were Krull et al. in 1965 [3]. Using infrared, optical
rotary dispersion and X-ray di¡raction techniques they found
polyglutamine to be in a L-sheet conformation. In the abstract
of their paper they note, ‘‘These observations indicate that
side-chain amides may associate with peptide amides in the
same or other molecules through hydrogen bonding T’’. They
pointed out that their own molecular models, as well as those
they had received in a personal communication from Elkan
Blout, founding editor of Biopolymers, indicated that poly-
glutamine was a highly aggregating molecule in a L-sheet
conformation. That polyglutamine forms aggregates and is
in a L-sheet conformation was independently rediscovered
by Max Perutz and colleagues [4]. They found the peptide
Asp2Gln15Lys2 to be highly aggregating with a large circular
dichroism (CD) peak at 197 nm.
The structure of polyglutamine as a monomer, however,
was still not known. We synthesized a peptide Lys2Gln15Lys2
[5]. This peptide was readily soluble in water at pH 7, and we
got a similar CD spectra to that of Perutz. However, ultra-
centrifugation analysis showed that this peptide also formed
large aggregates. We found that Robert Baldwin had made a
monomeric short basic peptide Ac-(Ala4Lys)3Ala-NH2 which
is 80% helical in aqueous solution [6]. We thought that by
£anking a polyglutamine stretch by such peptides we might
be able to get a water-soluble monomeric peptide. We synthe-
sized the peptide Ac-(Ala4Lys)3Gln9LysAla4LysAla-NH2. Ul-
tracentrifugation analysis showed that this peptide was mono-
meric. The CD spectra showed the peptide to be 59% random
coil, and 41% K-helix. We synthesized another peptide Ac-
TyrGlyAla2LysAla4LysGln17LysAla4LysAla-NH2. This pep-
tide was also found to be a monomer, with some nascent
aggregate formation. The CD spectra showed 67% random
coil, 26% K-helix, and 7% L-sheet. As the percentage of ran-
dom coil in the peptides increased with a larger number of
glutamines, and as the alanine/lysine containing segment of
our peptides were nearly identical to Baldwin’s helical peptide,
we concluded that polyglutamine was in a random coil con-
formation [5]. Furthermore, in previous work with poly-
[N5-(hydroxyalkyl-glutamine)] compounds it was found that
poly-[N5-(hydroxybutyl-glutamine)] was strongly helical in
aqueous solution, poly-[N5-(hydroxypropyl-glutamine)] mixed
helix and coil, and poly-[N5-(hydroxyethyl-glutamine)] all coil
[7,8]. Thus, we might expect polyglutamine itself to be in a
random coil, rather than helical conformation.
From recent modeling of a wheat protein containing a
number of short polyglutamine stretches, Masci et al. propose
that these polyglutamine stretches will be ‘‘unordered and
£exible’’ [9]. Also, they note that glutamine residues being in
a £exible con¢guration is supported by chain £exibility pre-
dictions of Karplus and Schulz [10].
Recently Sharma et al. [11] have studied peptides containing
polyglutamine stretches. In their abstract, they suggest ‘‘that
all the polyglutamine peptides with and without interrup-
tions(s) adopt a L-structure and not random coil’’. Sharma
et al. have studied four peptides Gln22, Gln8HisGlnHisGln8,
Gln10HisGlnHisGln10, and Gln8HisGln4HisGln8. For Gln22
they found a spectrum qualitatively similar to the one found
by Perutz. Their peak, however, is at 202 nm, rather than at
197 nm as in Perutz’ spectrum. They note that the histidine
containing compounds are more soluble in aqueous solution
than pure polyglutamine. They suggest that histidine plays a
‘major role’ in this solubility. However, we had already shown
that a peptide, Lys2Gln15Lys2, with more consecutive glut-
amines than any of the peptides of Sharma et al., is soluble
in aqueous solution at pH 7. Based on a blue-shifted positive
CD band in the 193^195 nm range, Sharma et al. conclude
that their Gln/His containing peptides are in intramolecular
L-sheet conformation. However, details of CD spectra can be
notoriously di⁄cult to interpret. The suggestion that a peptide
adopts an intramolecular L-sheet conformation requires dem-
onstration that the peptide is a monomer.
Sharma et al. suggest that histidine interruptions of poly-
glutamine stretches in the SCA1 protein promote protein sol-
ubility, and that loss of histidines in mutant proteins leads to
protein aggregation and disease. However, all SCA1 patients
have both a loss of histidines and an extended polyglutamine
stretch [12], which does not prove the suggestion of Sharma et
al.
As all evidence required to show that the peptides studied
by Sharma et al. are intramolecular L-sheets has not been
given, we stand by our demonstration that polyglutamine
stretches of moderate length, e.g. nine glutamines, are in a
random coil conformation. Even if peptides containing poly-
glutamine and histidine are in intramolecular L-sheets, this
does not imply that moderate length stretches of polyglut-
amine itself are in a L-sheet conformation.
In summary, to support their claim that their peptides form
intramolecular L-sheets, Sharma et al. would have to demon-
strate that their peptides are monomers. Even if they did so,
this does not imply that moderate length polyglutamine
stretches are in a L-sheet conformation. Future work using
NMR or other techniques may be able to study the structure
of polyglutamine in more detail using our monomeric poly-
glutamine containing peptides [5].
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We have recently studied the structure and aggregation
properties of a series of peptides containing polyglutamine
stretches in order to understand the mechanism of diseases
caused by polyglutamine expansion [1]. In particular, we
have used the SCA1 polyglutamine stretch as a model. Pep-
tides Q22, Q8HQHQ8, Q10HQHQ10, and Q8HQ4HQ8 were
synthesized to mimic the natural sequences present in the
SCA1 protein. Most of the normal SCA1 proteins (93%) carry
glutamine repeats interrupted by 1^2 histidine residues having
a con¢guration of QmHQHQm [2]. Mutant proteins, however,
carry expanded repeats that have lost the histidine residue
interruptions. Q21 was the longest uninterrupted tract seen
in normal individuals in SCA1. Our interest in the SCA1
protein was kindled by a report by Quan et al. [3], in which
they described an individual with 44 repeats in the SCA1
protein. Although the repeat length was well within the dis-
ease range for SCA1, the individual was normal. On sequenc-
ing, it was found that the glutamine repeat was interrupted
twice by an HQH con¢guration. Thus, although the number
of glutamine residues was within the disease range, their
pathological e¡ect seemed to be mitigated by the presence
of histidine interruptions.
Altschuler et al. [4] had studied synthetic peptides contain-
ing nine and 17 polyglutamine stretches £anked by other ami-
no acids (to make them water soluble) and concluded that the
glutamine stretches of moderate size adopt a random coil
conformation in the monomer form in solution. Earlier, Pe-
rutz et al. [5] had demonstrated the formation of aggregates of
L-sheet structure by the E2Q15K2 peptide both in solution and
in solid state.
Altschuler et al. [6] have asked for evidence of the mono-
meric state of peptides in solution studied by us. We feel that
they have overlooked the primary objective of our study. We
would like to reassert and strengthen our original observation
based on the solubility, concentration and temperature depen-
dent circular dichroism (CD) spectra and Fourier transform
infrared data shown in Sharma et al. [1]. We showed that in
the polyglutamine peptides with or without histidine interrup-
tion(s), the insolubility and aggregation phenomena occur
only after the formation of large (wide) intermolecular L-sheet
structures. However, polyglutamine peptides with histidine
residue interruptions undergo such aggregation at much high-
er concentrations compared to uninterrupted polyglutamine
tracts. Interrupted polyglutamine peptides with an HQH mo-
tif in the middle as observed in normal SCA1 proteins showed
the least propensity to form large L-sheet structures and hence
a lower aggregation potential. We showed that at low concen-
trations, the histidine residue interrupted peptides,
Q8HQHQ8, Q10HQHQ10, and Q8HQ4HQ8, exhibited a blue
shifted positive CD band in the range 193^195 nm, suggesting
that L-sheets formed by these peptides do not involve more
than two to three strands and these structures are mostly
intramolecular in nature [1]. In addition, the e¡ect of TFE
on the conformation was also investigated at di¡erent concen-
trations of the peptides (unpublished results). At low concen-
trations of Q8HQHQ8, Q10HQHQ10, Q8HQ4HQ8, an increase
in molar ellipticity at 220 nm was observed whereas at high
concentrations this increase was negligible. This suggests that
at low concentrations, the structure is primarily intramolecu-
larly hydrogen bonded and at high concentrations there is
formation of intermolecular L-sheet structure. This further
substantiates our earlier conclusion based on the observation
that these peptides at low concentration undergo reversible
thermal denaturation^renaturation unlike the Q22 peptide,
which forms irreversible disordered aggregates on denatura-
tion [1].
In order to carry out biophysical studies on the monomeric
state of polyglutamine containing peptides, we feel that
Altschuler et al. [4] have compromised on the biological rele-
vance of the peptide sequences they selected as models to
understand the etiology of polyglutamine diseases. They ques-
Table 1
Amino acid residues £anking the polyglutamine stretches in the pro-
teins associated with polyglutamine expansion diseases
N-terminal residues C-terminal residues
DRPLA H H Qn H H
HD S F Qn P P
SBMA L L Qn E T
SCA1 A E Qn a H L
SCA2 K P Qn P P
SCA3 F R Qn R D
SCA6 P P Qn A V
SCA7 A R Qn P P
aSCA1 is the only disease protein where the polyglutamine stretch is
interrupted by non-glutamine residues. The most common con¢gu-
ration observed is QmHQHQm.
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tioned our suggestion that histidine residues play a major role
in the solubility of polyglutamine tracts by citing their work
on K2Q15K2 and claimed that this peptide is soluble and
contains longer polyglutamine stretches than the peptides
studied by us. Our analysis indicates that this con¢guration
of £anking residues is never seen in any of the eight disease
proteins (DRPLA, SBMA, SCA1, SCA2, SCA3, SCA6,
SCA7, HD) involved in the various polyglutamine repeat dis-
orders (Table 1). Altschuler et al. have therefore used peptides
which, unlike ours, are not known to occur in any of the
disease proteins.
On the basis of our experiments, we have suggested that
histidine interruptions within the glutamine stretch of the
SCA1 protein promotes solubility and prevents aggregation
[1]. Altschuler et al. [6] note that for our model to be correct,
there should be both a loss of histidine residues and an ex-
pansion of the glutamine stretch. They are mistaken in that
they consider these two events to be independent of each
other. In the case of SCA1, the polyglutamine tract (encoded
by the CAG repeat) is interrupted by two histidine residues
(encoded by CAT) in normal individuals, whereas in the case
of SCA2, CAG repeats are interrupted by CAA triplets, also
encoding glutamine [7]. In both cases, loss of interruption of
the CAG repeat by point mutation predisposes to the expan-
sion of CAG repeats, leading to a long stretch of uninter-
rupted glutamine repeats and subsequent disease [2,7,8]. Our
model is also validated by the ¢ndings of Quan et al. [3] that
long glutamine stretches fail to evoke disease pathology when
interrupted by histidine residues even when the length of the
repeat is in the ‘disease range’. To further test this we have
also synthesized the Q44 peptide with two HQH interruptions
and found it to be soluble (unpublished result). We therefore
feel that our model of modulation of aggregation by histidine
interruptions still holds true. Further studies should be carried
out on polyglutamine peptides £anked by sequences that are
similar to the natural context, rather than peptides used by
Altschuler et al. that are not found in the context of the
disease proteins.
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